2.00
+0.25(+14.29%)
Currency In USD
| Previous Close | 1.75 |
| Open | 1.74 |
| Day High | 2 |
| Day Low | 1.74 |
| 52-Week High | 12.54 |
| 52-Week Low | 1.17 |
| Volume | 286,736 |
| Average Volume | 258,255 |
| Market Cap | 9.27M |
| PE | -0.38 |
| EPS | -5.26 |
| Moving Average 50 Days | 1.8 |
| Moving Average 200 Days | 3.02 |
| Change | 0.25 |
If you invested $1000 in IN8bio, Inc. (INAB) since IPO date, it would be worth $200 as of December 25, 2025 at a share price of $2. Whereas If you bought $1000 worth of IN8bio, Inc. (INAB) shares 3 years ago, it would be worth $1,098.9 as of December 25, 2025 at a share price of $2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
GlobeNewswire Inc.
Oct 29, 2025 12:00 PM GMT
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State Universit
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that potentially allows for safer deep B